The FDA approved updated 2025 COVID-19 vaccines but limited authorization to people 65 and older and younger individuals with at least one high-risk condition. Novavax's protein-based vaccine is authorized only for people 12 and older under the same risk-based criteria. One previously available vaccine for young children was removed from authorization. The CDC's vaccine advisory panel is expected to meet within a month to issue formal recommendations. Prior federal guidance had recommended vaccination for everyone 6 months and older. The FDA decision does not immediately change vaccine rollout or access, and insurance coverage may be affected.
The FDA approved updated COVID-19 shots on Wednesday, but limited their use for many Americans, recommending them only for people 65 and older or those younger with a health condition that puts them at higher risk. The FDA also removed one of the two vaccines available for young children. The big thing to know right now: The FDA's decision does not mean the vaccines are now immediately rolling out or that access to vaccines has been limited effectively immediately.
But on Wednesday, the FDA said that the updated COVID-19 shots from Pfizer, Moderna and Novavax are approved for people at higher risk from the disease, which is: Everyone age 65 and older Younger adults and children with at least one high-risk health condition (also called comorbidities) such as asthma or obesity. Novavax's shot is only open to people 12 or older, under the same risk-based restrictions now in place for the Moderna and Pfizer options.
Collection
[
|
...
]